New work from Fred Hutch Cancer Center virologists shows that gene drive, which pushes a trait through a population, occurs ...

Shifting”, “Trojan Horse”, Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR ...

Adetona Fayemiwo is an Associate Professor of Medicine, Consultant Clinical Microbiologist, and Head of the Department of ...

In this review, we summarize the current understanding of MRI findings of viral encephalitis, especially related to HSV, HIV ... of the lesions at the acute phase of the illness.

A study presented at UEG Week 2024 has uncovered distinct antibody responses in Crohn's disease and ulcerative colitis before ...

Herpes Labialis Treatment Market. The global herpes labialis treatment market is poised for substantial growth, with a ...

occurs when the patient has no antibodies to HSV-1 or HSV-2. It is expected to present as a severe and prolonged episode (up to 21 days) of multiple coalescent vesicular-ulcerative lesions with ...

A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered ...

That virus includes designer DNA called a gene drive that spreads from one herpes simplex virus to another. And it may be a first step toward an entirely new way of treating the infection ...

The World Health Organization said on X on Monday that the second phase of a polio vaccination campaign had started in ...

Vast Space unveiled the design of the space station it plans to propose to NASA in the next phase of the agency’s program to develop commercial successors to the International Space Station.

The phase 2 trial will test a 30 µg dose of the shot in around 200 adult volunteers in the US who have already received one booster dose at least 90 days before enrolment, said Pfizer.